Precigen, Inc.
NASDAQ:PGENBiotechnology
-$0.10 today
- Market cap
- $1.53B
- Beta
- 1.06
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.65
Volume 4.27M
Average 4.72M
PGEN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Precigen, Inc.NASDAQ: PGEN
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA turns positive
Q2 FY2026 EBITDA was $24.13M, compared with -$27.23M a year earlier. Trailing-twelve-month EBITDA was -$143.84M.
Context
- EBITDA amounted to 2515.2% of revenue in FY2025, down 631.2 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of $126.28M (+151.8%) for the fiscal year ending Dec 2026, a step up from the -97.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $24.13M+715.1% QoQ
- Last fiscal yearDec 2025
- -$243.57M-97.2% YoY
- LTMJun 2026
- -$143.84M-16.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +188.6% | +125.8% | -62.9 pp |
| 1 year | -97.2% | +151.8% | +249.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (243.57M) USD
- Year-over-year change
- -97.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (243.57M) | -97.2% |
| FY2024 | 2024-12-31 | (123.5M) | -38.4% |
| FY2023 | 2023-12-31 | (89.23M) | -42.9% |
| FY2022 | 2022-12-31 | (62.43M) | +19.6% |
| FY2021 | 2021-12-31 | (77.64M) | — |
EBITDA vs competitors
How PGEN compares with its peers on the latest reported figures
- PGEN's LTM Jun 2026 EBITDA of -$143.84M is the 4th highest of the 8 companies compared; the peer median is -$194.47M.
- Its year-over-year change of -16.8% is the 6th highest of 8, against a peer median of +21.0%.
- EBITDA amounts to 167.8% of revenue for PGEN, versus a peer median of 383.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $73.43M | +298.8% | — | 505.0% | |
| LTM Mar 2026 | -$40.42M | -143.9% | — | 89.7% | |
| LTM Mar 2026 | -$100.08M | +56.8% | — | 258.7% | |
| LTM Jun 2026 | -$143.84M | -16.8% | — | 167.8% | |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
| LTM Mar 2026 | -$229.35M | -87.3% | — | 261.2% | |
| LTM Mar 2026 | -$384.61M | +25.4% | — | 581.9% | |
| LTM Sep 2026 | -$482.67M | -3.6% | — | 1917.5% | |
| Peer median (excluding PGEN) | -$194.47M | +21.0% | — | 383.1% | |
Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.27M | 26.91M | 6.23M | 3.93M | 9.68M |
| Cost of Revenue | 53.68M | 6.34M | 6.12M | 4.27M | 6.1M |
| Gross Profit | (39.41M) | 20.57M | 106K | (342K) | 3.59M |
| Gross Margin | -276.2% | 76.4% | 1.7% | -8.7% | 37.1% |
| Research & Development | 47.93M | 47.17M | 48.61M | 53.07M | 40.06M |
| Selling, General & Admin | 0 | 48.01M | 40.42M | 41.29M | 70.13M |
| Operating Expenses | 52.54M | 96.3M | 99.86M | 134.69M | 110.19M |
| Depreciation & Amortization | 13.76M | 10.77M | 6.67M | 4.53M | 3.2M |
| EBITDA | (77.64M) | (62.43M) | (89.23M) | (123.5M) | (243.57M) |
| EBITDA Margin | -544.2% | -232.0% | -1433.3% | -3146.4% | -2515.2% |
| Operating Income | (91.95M) | (75.73M) | (99.76M) | (135.03M) | (106.6M) |
| Operating Margin | -644.5% | -281.4% | -1602.5% | -3440.2% | -1100.8% |
| Interest Income | 171K | 133K | 3.24M | 1.42M | 3.22M |
| Interest Expense | 18.76M | 6.77M | 468K | 6K | 3.87M |
| Other Income / Expenses | (19.02M) | (4.24M) | 3.4M | 7M | (144.04M) |
| Income Before Tax | (110.97M) | (79.97M) | (96.36M) | (128.03M) | (250.64M) |
| Pre-Tax Margin | -777.8% | -297.2% | -1548.0% | -3261.9% | -2588.2% |
| Income Tax Expense | (160K) | (189K) | (458K) | (1.79M) | 3K |
| Net Income | (92.17M) | 28.32M | (95.9M) | (126.24M) | (250.64M) |
| Net Margin | -646.0% | 105.2% | -1540.6% | -3216.2% | -2588.2% |
| EPS (Basic) | (0.47) | (0.33) | (0.39) | (0.47) | (1.41) |
| EPS (Diluted) | (0.47) | (0.40) | (0.39) | (0.47) | (1.41) |
| Weighted Avg Shares | 197.76M | 200.36M | 244.54M | 267.73M | 304.71M |
| Weighted Avg Shares (Diluted) | 197.76M | 200.36M | 244.54M | 267.73M | 304.71M |
Precigen, Inc.
NASDAQ:PGEN
Intrinsic Alpha fair value
Locked
Current Price
$4.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.